menu

RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option

close
0.25 credits
15 minutes
RAASi Therapy, Diabetes, and Hyperkalemia: Halting Therapy Is NOT the Only Option
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    George L. Bakris, MD
    Professor of Medicine
    Director, Am Heart Assoc. Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, IL

    Consulting Fees: Alnylam, Ionis, Merck, Relypsa

    Faculty:
    Biff F. Palmer, MD
    Professor of Internal Medicine
    University of Texas Southwestern Medical Center
    Dallas, TX

    Nothing to disclose.

    Reviewers/Content Planners/Authors:

    • Nancy Ashley, MSN, APRN, ANP-BC, CCRN, CEN, has nothing to disclose.
    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Biff F. Palmer, MD, has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the benefit of RAAS inhibitors in patients with diabetes, hypertension (HTN), and CKD and the importance of titrating to the highest tolerated recommended dose
    • Identify obstacles to optimizing dosing of RAAS inhibitors in patients with diabetes, HTN, and CKD and the importance of monitoring serum potassium and creatinine levels
    • Describe the use of potassium binders for the management of hyperkalemia, when possible, as an alternative to discontinuing RAASi therapy
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, primary care physicians, nurse practitioners, nurses, and all allied healthcare professionals involved in the diagnosis and treatment of HF and CKD.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    George L. Bakris, MD
    Professor of Medicine
    Director, Am Heart Assoc. Comprehensive Hypertension Center
    University of Chicago Medicine
    Chicago, IL

    Consulting Fees: Alnylam, Ionis, Merck, Relypsa

    Faculty:
    Biff F. Palmer, MD
    Professor of Internal Medicine
    University of Texas Southwestern Medical Center
    Dallas, TX

    Nothing to disclose.

    Reviewers/Content Planners/Authors:

    • Nancy Ashley, MSN, APRN, ANP-BC, CCRN, CEN, has nothing to disclose.
    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • Biff F. Palmer, MD, has nothing to disclose.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the benefit of RAAS inhibitors in patients with diabetes, hypertension (HTN), and CKD and the importance of titrating to the highest tolerated recommended dose
    • Identify obstacles to optimizing dosing of RAAS inhibitors in patients with diabetes, HTN, and CKD and the importance of monitoring serum potassium and creatinine levels
    • Describe the use of potassium binders for the management of hyperkalemia, when possible, as an alternative to discontinuing RAASi therapy
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, primary care physicians, nurse practitioners, nurses, and all allied healthcare professionals involved in the diagnosis and treatment of HF and CKD.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Dedicated to the creation and execution of the highest quality, evidence-based continuing medical education (CME) initiatives, we utilize multiple learning opportunities for the primary goal of improving healthcare delivered to patients through sharing of research, knowledge, and clinical practice skills.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 7/27/21